Single sequencer. Multiple applications. Now more scalable than ever.

 

Yes, with the Ion GeneStudio S5 Series flexible chip format, your research accelerates across both small and large projects without the need to change instruments. The fast, automated workflow achieves sample-to-answer results across a broad range of applications.

Get more
  • Speed
  • Scalability
  • Simplicity
From less
  • Small sample input
  • Minimal hands-on time

Meet the Ion GeneStudio S5 systems


Five Ion 5 Series chips

Figure 1. Five Ion 5 Series chips achieve 2–130M reads per run to enable a broad range of applications. Reads per run shown are maximum reads per chip.

Learn more about Ion GeneStudio S5 Series sequencing ›


RNA applications

RNA applications

The Ion GeneStudio S5 Series enables applications from mRNA gene expression profiling to whole transcriptome sequencing.

Microbial and infectious diseases

Microbial and infectious diseases

A flexible chip format enables you to cost-effectively process samples without batching—explore species diversity and abundance with the higher dynamic range achieved by the Ion GeneStudio S5 Series.

Inherited disease

Inherited disease

Fixed, Made-to-Order, and On-Demand Ion AmpliSeq panels help you discover causal variants easily with a simple and fast Ion GeneStudio S5 sequencing workflow with nucleic acid-to-answer automation.

Cancer

Cancer

Highly-referenced, single-platform solutions enabling low- and ultra-low sample inputs to comprehensively profile even the most challenging FFPE, liquid biopsy and immuno-oncology research samples.


Fast results. Consistent answers. Sample to answer automation.

Speed and flexibility improve lab competitiveness

“In my institute, many customers outsource for exome and whole genome studies.  They come to me for speed, and flexibility for different gene panels, tailored to disease areas of interest.  This is the most elegant workflow on the market today, and I can now offer a range of applications and deliver the data in the fastest turnaround time in the market, at costs that are competitive.” 

—Morten Dunoe, Lab Manager, Molecular Genetic Laboratory, Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Denmark